---
schema_version: "secwatch.filing_event.v1"
accession: "0001723128-26-000008"
form_type: "8-K"
ticker: "AMRX"
cik: "0001723128"
company_name: "Amneal Pharmaceuticals, Inc."
filed_at: "2026-02-27T23:59:59+00:00"
generated_at: "2026-05-15T23:07:05.343507+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Amneal reports Q4 2025 net revenue $814M (+11% YoY); FY25 rev $3.02B; 2026 guidance $3.05-$3.15B

## Summary
- Q4 2025 net revenue $814M (+11% YoY); GAAP net income $35M; diluted EPS $0.11.
- Full year 2025 net revenue $3.02B (+8% YoY); GAAP net income $72M; diluted EPS $0.22.
- Adjusted EBITDA FY25 $688M (+10% YoY); Q4 adj EBITDA $175M.
- FY25 adj diluted EPS $0.83 vs $0.58 prior year; Q4 adj EPS $0.21 vs $0.12.
- 2026 guidance: net revenue $3.05-$3.15B, adj EBITDA $720-$760M, adj EPS $0.93-$1.03.

## SEC filing metadata
- accession: 0001723128-26-000008
- form_type: 8-K
- ticker: AMRX
- cik: 0001723128
- company_name: Amneal Pharmaceuticals, Inc.
- filed_at: 2026-02-27T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1723128/000172312826000008/0001723128-26-000008-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1723128/000172312826000008/amrx-20260227.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001723128-26-000008
- JSON: https://secwatch.observer/filing/0001723128-26-000008.json
- Plain text: https://secwatch.observer/filing/0001723128-26-000008.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.